中国内镜杂志2011，Vol.17Issue(8)：795-797,801,4.
CYP2C10基因多态性对奥美拉唑治疗十二指肠溃疡的影响
Effects of genotypic differences of CYP2C19 on duodenal ulcer therapy with omeprazole
李浩 1吴金术 1张伟 2龚连生 3刘刚 3刘勤 3谭亮 3王荣兵3
作者信息
- 1. 湖南省人民医院肝胆外科,湖南长沙410002
- 2. 中南大学临床药理研究所,湖南长沙410078
- 3. 中南大学湘雅医院卫生部肝胆肠外科中心,湖南长沙410008
- 折叠
摘要
Abstract
[Objective] We intended to evaluate endoscopically a cure rate for Helicobacter pylori infection by dual rabeprazole/amoxicillin therapy in relation to CYP2C19 genotype status prospectively. [Methods] Sixty-five patients with gastritis and H.pylori infection completed the dual therapy with 20 mg of omeprazole bid, 1000 mg of amoxicillin bid and clarithromycin 500 mg bid for 1 week. Then omeprazole was medicated at the dose of 20 mg bid to inhibit gastric acid secretion. CYP2C19 genotype status was determined by a PCR-restriction fragment length polymorphism method. The symptomatic and endoscopic evaluation was performed at the baseline and 4-week post-treatment periods. [Results] Of the 65 patients, 24 were homozygous extensive metabolizers (homEM), 31 were heterozygous extensive metabolizers (hetEM), and 10 were poor metabolizers (PM). Significant differences in healingrates of duodenal ulcer among the homEM, hetEM and PM groups were observed: 75.0%, 90.3%, and 100%, respectively (P<0.05). Cure rate in H.pylori infection PM patients was significantly (P<0.05) greater than in homEM and hetEM patients, respectively. [Conclusions] The cure rates for duodenal ulcer and H.pylori infection by dual omeprazole/amoxicillin therapy depend on the CYP2C19 genotype status. The genotyping test of CYP2C19 appears a clinically useful tool for the optimal dual treatment with omeprazole plus amoxicillin.关键词
CYP2C19/基因多态性/奥美拉唑/幽门螺旋菌Key words
CYP2C19/ genetic polymorphis/ omeprazole/ Hpylori分类
医药卫生引用本文复制引用
李浩,吴金术,张伟,龚连生,刘刚,刘勤,谭亮,王荣兵..CYP2C10基因多态性对奥美拉唑治疗十二指肠溃疡的影响[J].中国内镜杂志,2011,17(8):795-797,801,4.
